ValuEngine upgraded shares of Amyris (NASDAQ:AMRS) from a strong sell rating to a sell rating in a research note published on Friday morning.
Several other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Amyris from a hold rating to a sell rating in a research note on Tuesday, January 30th. B. Riley began coverage on shares of Amyris in a research note on Thursday, January 25th. They issued a buy rating and a $8.00 target price for the company. HC Wainwright reaffirmed a buy rating and issued a $15.00 target price on shares of Amyris in a research note on Thursday, January 18th. Finally, Cowen reaffirmed a hold rating and issued a $4.00 target price on shares of Amyris in a research note on Wednesday, November 29th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $7.69.
Shares of Amyris (NASDAQ:AMRS) opened at $5.78 on Friday. The company has a market cap of $248.73, a P/E ratio of -0.93 and a beta of 0.49. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78. Amyris has a 12 month low of $1.86 and a 12 month high of $10.65.
A number of hedge funds have recently added to or reduced their stakes in AMRS. Tanaka Capital Management Inc. grew its stake in shares of Amyris by 72.0% during the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 221,295 shares during the period. Hudson Bay Capital Management LP purchased a new stake in shares of Amyris during the 4th quarter valued at $451,000. Carl Domino Inc purchased a new stake in shares of Amyris during the 3rd quarter valued at $182,000. Creative Planning purchased a new stake in shares of Amyris during the 4th quarter valued at $188,000. Finally, KBC Group NV grew its stake in shares of Amyris by 228.4% during the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 41,834 shares during the period. 22.71% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “ValuEngine Upgrades Amyris (AMRS) to “Sell”” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3224868/valuengine-upgrades-amyris-amrs-to-sell.html.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.